What similarly acting projects are still unpartnered?

The small cap biotech Instil Bio tries to follow in Summit’s slipstream.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

The company defends its cancer strategy, and says it's not a me-too developer.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.